Open company graph database — free web & API
Login

Sanofi

サノフィAlias
Ticker
Listed market
Euronext
Country
France
Employees (non-consolidated)
74,846
Related companies
0
§01

Basic information

BASIC
Head office
46 Avenue of the Great Army, 75017 Paris, France
Chief executive
Belen Garijo
Employees (non-consolidated)
74,846 people
Employees (consolidated)
Start date
1994-01-01
End date
§02

Websites

1 DOMAINS
§03

Business

1
insulin production
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

29 EVENTS

FitzGerald was appointed professor of hygiene at the University of Toronto in 1913.Sources

On May 1, 1914, the University of Toronto officially established the Antitoxin Laboratories.Sources

On October 25, 1917, FitzGerald’s expanded operation was officially named the Connaught Antitoxin Laboratories and University Farm, after the Duke of Connaught, Canada’s wartime governor general.Sources

In the 1920s, Connaught grew rapidly following the discovery of insulin at the University of Toronto and the development of large-scale production methods. Connaught Labs also conducted the first field trials of diphtheria toxoid, establishing its effectiveness as an immunizing agent.Sources

Other important products pioneered in the 1930s included fresh-strain pertussis vaccine and heparin, a blood anticoagulant.Sources

In the 1950s, Connaught scientists enabled Jonas Salk to develop a safe inactivated polio vaccine. Connaught’s new synthetic Medium 199 provided a safe base, while the "Toronto Method" of producing rocked-bottle cultures allowed enough poliovirus fluids to be produced for an unprecedented US field trial of Salk’s vaccine in 1954.Sources

An unprecedented US field trial of Salk’s vaccine.Sources

After introducing DPT-Polio vaccine in 1959, Connaught launched an intensive effort to produce the first trivalent Sabin live oral polio vaccine.Sources

In addition to new vaccines against influenza and measles, a freeze-dried smallpox vaccine was developed in the 1960s, which, along with Connaught’s other contributions, played a major role in the global eradication of smallpox.Sources

Green Santa, launched with Beautiful Store, was established in 2004. It has since become Sanofi’s CSR program and an exemplary long-running CSR initiative in Korea’s pharmaceutical industry.Sources

By donating the Beautiful Store branch at Gangnam-gu Office Station, also known as the Green Santa Store, and through regular employee volunteering and donations of recyclable goods, we contribute to environmental protection through resource circulation and to sharing with the local community.Sources

For children with chronic rare and intractable diseases, we selected 100 books for the Green Santa Beautiful Bookshelf, recommended by 100 prominent figures of our time, and donated bookshelves to hospital schools, local children’s centers, and patient respite centers across the country. We also held a traveling exhibition at seven libraries in Seoul.Sources

Since 2013, we have offered an integrated cultural arts education program through the Green Santa Imagination School.Sources

To encourage greater public interest in rare diseases, Sanofi has sponsored the large-scale, public-participation charity event “Good Steps: Walk for Six Minutes” since 2014.Sources

In 2019, Sanofi partnered with the Korean Diabetes Association on the Challenge 100 project, highlighting the importance of healthy lifestyle habits and exercise in preventing diabetes. At the event, held against the backdrop of Haeundae in Busan, families, couples, and friends took part in physical activities together and gained a meaningful understanding of the importance of diabetes prevention.Sources

Since 2019, Sanofi has been running campaigns to raise awareness of severe atopic dermatitis.Sources

In 2020, under the title “I Am a Gapeun Person,” the painful symptoms experienced by patients were described using the coined word “gapeuda,” combining the Korean words for “itchy” and “painful.”Sources

2020 Green Santa Online Imagination SchoolSources

In 2020, under the title “I Am a Gapeun Person,” the painful symptoms experienced by patients were described using the new word “gapeun,” combining the Korean words for “itchy” and “painful.” The campaign also shared the stories of patients overcoming their suffering and finding meaning of their own.Sources

In 2021, the “I Am a Sokgapeun Person” campaign was held.Sources

2021 Green Santa Online Imagination SchoolSources

In 2021, the campaign “I Am a Sokgapeun Person” built on the 2020 campaign’s coined term “gapeun” (itchy and painful) by adding “sok,” meaning “inside,” to convey not only the physical pain of people with atopic dermatitis but also their emotional distress. Through comics and video content, the campaign offered support to teenagers facing the difficult combination of severe atopic dermatitis and adolescence, and helped improve parents’ awareness of the disease.Sources

Dangdang Care is an application that uses digital technology to provide people with diabetes with self-management and emotional support. It was developed in October 2021 in partnership with the Korean Diabetes Association.Sources

In 2022, the “I Am Someone Who Cannot Sleep” campaign was held.Sources

In 2022, Sanofi-Aventis Korea launched “I Am Someone Who Cannot Sleep,” connecting people with atopic dermatitis who cannot sleep because of itching and pain with the public through the universally relatable theme of sleep. An atopic dermatitis exhibition, a concert, and a sleep-themed market helped raise public awareness of the symptoms and challenges of severe atopic dermatitis.Sources

Presentation of the 2022 Green Santa Imagination School impact studySources

In 2023, the “My Flaw: Home” pop-up exhibition helped raise awareness of the severity of the symptoms experienced by people with severe atopic dermatitis and their impact on daily life, as well as social understanding of the disease.Sources

Under the theme “Records of Home, Food, and Sleep Etched on an Itchy, Painful Body,” the “My Flaw: Home” pop-up exhibition was held in 2023. It featured a variety of content related to the “home, food, and sleep” of people with atopic dermatitis, including generative AI drawings, media art, and interactive content. In particular, five people with severe atopic dermatitis took part as artists in the generative AI drawings, adding special significance to the exhibition. The pop-up exhibition helped increase understanding of atopic dermatitis and raise public awareness of the suffering of those affected.Sources

In 2026, we dedicated the Charles Best Building at our Toronto Campus, honouring one of Canada’s most influential medical pioneers.Sources

§07

News

22 ARTICLES

Sanofi’s VaxRabeo Approved in EU for All AgesSources

Sanofi announced that the European Commission has approved its next‑generation rabies vaccine, VaxRabeo, for pre‑exposure and post‑exposure prophylaxis in all age groups. This marks the first marketing authorisation for the vaccine, following a positive opinion from the EMA’s Committee for Medicinal Products.

Infilbray Approved for Neurological GD3Sources

The US FDA approved Sanofi’s Infilbray as the first medicine to treat neurological manifestations of Type 3 Gaucher disease (GD3). The once-daily oral medicine acts across the blood-brain barrier and targets neurological manifestations associated with GD3, a chronic neuronopathic form involving the central nervous system.

Sanofi Q3 2026: Growth and Upgraded GuidanceSources

Sanofi reported Q3 2026 sales growth of 14.3% at CER and business EPS of €3.55, and upgraded its FY 2026 guidance. Pharma launches sales rose 31.4% to €1.4 billion, while Dupixent sales increased 34.8% to €5.7 billion. Vaccines sales decreased 6.6% to €3.2 billion.

Duvakitug Maintains Positive Outcomes in IBDSources

Sanofi and Teva reported new Phase 2b data showing duvakitug maintained positive outcomes through Week 44 in ulcerative colitis and Crohn’s disease. In both conditions, patients maintained high rates of clinical and endoscopic outcomes. Duvakitug was well tolerated.

Sanofi Begins Construction of New Insulin Production Facility in GermanySources

On October 19, 2026, Sanofi commenced construction of a new insulin production facility at BioCampus in Frankfurt, Germany. The facility will introduce next-generation insulin production, strengthening the ability to provide a stable supply to millions of people over the long term.

Sanofi to Sponsor Tour de France White JerseysSources

Sanofi will become the first company to sponsor the white jersey at both the Tour de France and the Tour de France Femmes avec Zwift. The jersey recognizes the best rider under 25 in the general classification.

Availability of the aide-mémoire for Q3 2026 resultsSources

Sanofi announced the availability of the aide-mémoire for its Q3 2026 results on the Investors page of sanofi.com. The document, prepared each quarter, supports financial modelling by covering non‑comparable items, foreign currency impact, and share count. The Q3 2026 results will be published on October 30, 2026.

Sanofi & Regeneron Expand AllianceSources

Sanofi and Regeneron have broadened their global partnership by adding new next‑generation, long‑acting immunology antibodies to the alliance. The addition includes REGN20423, a clinical‑stage IL‑13 monoclonal antibody, a long‑acting IL‑4xIL‑13 bispecific, and two other pre‑clinical long‑acting antibodies developed by Regeneron. Regeneron will receive an upfront payment of $1 billion, with the potential for up to an additional $7 billion in future milestone payments.

Europe Is Losing the Pharma Investment RaceSources

The chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi say Europe is losing the pharmaceutical investment race, but that a comeback is within reach. They emphasize their companies’ European roots and their responsibility to protect their future so they can continue developing life-changing medicines for patients.

Sanofi partners with CheplapharmSources

Sanofi and Cheplapharm announced a strategic partnership in which Cheplapharm will take over 20 mature medicines and three manufacturing sites worldwide. In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm.

§09

Sources & updates

SOURCES
↑